Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).

Sotio Biotech

11/7/2021

Cancer control in the Czech Republic: Findings from the Index of Cancer Preparedness (2021)

By Economist Intelligence Unit, sponsored by SOTIO and PPF.

One of Europe’s ageing societies, the Czech Republic faces a growing cancer burden. Its response to cancer has been strong, helped by a generous health insurance system, a skilled workforce and advanced infrastructure. But to accelerate success, more coordination of resources is needed, as is greater attention to patient-centred care.

This independent report discusses the strengths and weaknesses of the Czech cancer response, based on parameters of the Index of Cancer Preparedness.

Introductory word of Radek Špíšek, CEO, SOTIO

To download the ICP report 

Introduction

Cancer is the second most common cause of death in the Czech Republic after cardiovascular diseases, explaining nearly 27% of all deaths.[1] In 2020, there were around 67,000 new cases of cancer in the Czech Republic and 27,000 deaths.[2] With a median age of 43.3 years, the Czech Republic is among the top 30 oldest societies[3] and as other European nations, is ageing.[4] This signals that the cancer challenge is likely to continue to grow. By 2030, it is estimated that new cases will rise to about 76,000 and deaths to about 32,500.[5]

Go to detail

Executive Summary

The Czech Republic faces an important cancer challenge. Cancer is the second most common cause of death today and, as an ageing society, the number of new cases is expected to increase in the next decade. High prevalence of risk factors such as smoking, obesity and physical inactivity may also contribute to this trend. But the country’s response to cancer is strong, even if there are signs that this is not a well coordinated effort. The country is ranked 8th among 29 countries examined in the Index of Cancer Preparedness (ICP) based on the quality of its cancer control actions.

Go to detail

The Index of Cancer Prepardness

This report follows The Economist Intelligence Unit’s 2019 publication Cancer preparedness around the world: National readiness for a global epidemic, which evaluated 28 countries around the world. This report specifically examines the recent inclusion of the Czech Republic in the assessment.

Go to detail

Overall Findings for the Czech Republic

Go to detail

Next Articles

Overall Findings for the Czech Republic

Care Delivery

Overall Findings for the Czech Republic

Policy and Planning

Overall Findings for the Czech Republic

Health system and governance

Conclusion

The Czech Republic faces an important cancer burden, but the country’s response to cancer is strong so far. Some of the country's strengths include: a well-established, high-quality population-based cancer registry providing a foundation for effective cancer tracking and action, and high-quality Complex Oncology Centres offering specialised care, some with research capabilities. There is also a wide reach of immunisation, screening services and treatments thanks to encompassing health insurance available to the population. Infrastructure is a particular strength as is the availability of skilled healthcare professionals.

Go to detail

The findings of this report are based on the assessment of the Czech Republic using the framework of the Index of Cancer Preparedness, desk research, as well as interviews with local experts who validated findings and offered additional nuances.

Our thanks are due to the following for their time and insight (listed alphabetically):

  • Jirina Bartunkova, Board of the Czech Society of Immunology; Head of the Department of Immunology of the 2nd Faculty of Medicine of Charles University in Prague & Motol University Hospital
  • Veronika Cibulova, General Secretary of the patient organization VERONICA
  • Tomas Dolezal, Managing Director of the Institute of Health Economics and Technology Assessment (iHETA)
  • Jana Prausova, President of the Czech Society for Oncology
  • Miroslav Specian, Board Member of the Hippokrates Endowment Fund.

 

Share on social networks

Share on social networks

Print

Download as PDF

Copy link

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases